CME Symposium: Optimizing Risk Reduction in the Acute Coronary Syndrome Patient

CHICAGO - April 1, 2014 - PRLog -- Optimizing Risk Reduction in the Acute Coronary Syndrome Patient: Facing the Challenges

Faculty
Lynne Braun, PhD, CNP, FAHA, FAAN (Chair)
Professor of Nursing
Rush University College of Nursing
Chicago, Illinois

Deepak Bhatt, MD, MPH
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joanna Sikkema, DNP, MSN, ANP-BC, FAHA, FPCNA
Assistant Clinical Professor
University of North Dakota
Grand Forks, North Dakota

Click To Register Online

Dual oral antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor, for the management of patients experiencing an acute coronary syndrome (ACS), has demonstrated significant improvements in the prevention of recurring major cardiovascular events versus aspirin alone. The realization that a significant number of ACS patients experience thrombotic events while on dual antiplatelet therapy with aspirin and clopidogrel, together with the extensive research on
clopidogrel resistance and the awareness that poor metabolizers of clopidogrel are associated with higher cardiovascular event rates following ACS or PCI, has provided the rationale for prasugrel and ticagrelor. While clopidogrel, prasugrel, and ticagrelor are all P2Y12 receptor inhibitors, they have distinct pharmacologic properties. Both prasugrel and ticagrelor have been studied separately against clopidogrel, on a background of aspirin therapy, in the setting of ACS; the study results have led to the inclusion of prasugrel and ticagrelor in ACS clinical practice guidelines.

After hospital discharge, ACS patients require efficient transitions of care to prevent the recurrence of major cardiovascular events. In addition to oral antiplatelet therapy after an ACS, a number of interventions (lifestyle and pharmacologic), based on clinical trial evidence and evolving clinical practice guidelines, are recommended to reduce the risk of another ischemic event, and patient adherence is critical. Therefore, in this program, experts will describe the changing landscape of oral antiplatelet therapy for patients with ACS, and identify best practices in secondary prevention

This continuing nursing education (CNE) activity is provided by Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, and sponsor of NCNP. LWW is co-providing this activity with Voxmedia and will award a maximum of 1.5 contact hours for this CNE activity.

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation

This live event is also provider approved by the California Board of Registered Nursing, Provider Number CEP 1149 for 1.5 contact hours. LWW is also an approved provider by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.

Lippincott Williams & Wilkins & Williams (LWW) will award 1.5 contact hours that can be applied to advanced pharmacology requirements.

LWW and Voxmedia International gratefully acknowledge the educational grant provided by AstraZeneca Pharmaceuticals LP.

Pre-registration is for planning purposes only.
You must register for the NCNP meeting here in order to attend.
For additional CME activities and online CME courses visit CMEPlanet

Photos:
https://www.prlog.org/12303717/1
https://www.prlog.org/12303717/2